Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin, type I cytoskeletal 10 (KRT10), is a member of the type I (acidic) cytokeratin family and an intermediate filament protein predominantly expressed in suprabasal keratinocytes of the epidermis[1][2][3][4][5]. KRT10 forms heterodimers with keratin 1 to establish a robust cytoskeletal network that confers structural integrity and resilience to the skin, contributing to the epidermal barrier and differentiation[4][5]. Mutations in KRT10 are associated with skin diseases such as epidermolytic ichthyosis (epidermolytic hyperkeratosis), and its aberrant expression has also been implicated as a marker for tumor invasiveness and poor prognosis in cancers such as hepatocellular carcinoma[3][5]. Despite its importance in structural functions, KRT10 is not a classical therapeutic target like receptors, enzymes, or transporters but is used diagnostically and as a biomarker in skin and cancer pathology[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin, type I cytoskeletal 10 (KRT10).